Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 6Completed 2Withdrawn 1Unknown 1Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 57Recurrence 7Neoplasms, Plasma Cell 5Neoplasms 4Smoldering Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Immunoglobulin Light-chain Amyloidosis 1Glioblastoma 1Disease 1Chromosome 17 deletion 1

Interventions

Dexamethasone 7ixazomib 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Cyclophosphamide 3Calcium Dobesilate 3Bortezomib 3Clinical Protocols 2venetoclax 1siltuximab 1pomalidomide 1isatuximab 1daratumumab 1X-Rays 1Valganciclovir 1Therapeutics 1Specimen Handling 1Polymerase Chain Reaction 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1MLN2238 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Biopsy 1Antiviral Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Immunoglobulin Light-chain Amyloidosis × daratumumab × Clear all
NCT03283917 2026-02-27

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
21 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡